hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06261606 id: 4020286 briefTitle: Feasibility of a Multifaceted Program to Reduce Cardiovascular Complications of Air Pollution overallStatus: RECRUITING date: 2024-01-28 date: 2024-03 date: 2024-03 date: 2024-02-15 date: 2024-03-05 name: Parham Sadeghipour class: OTHER briefSummary: The main goal of this clinical trial is to evaluate the feasibility of conducting a large-scale clinical trial testing a program containing several aspects for reducing the effects of air pollution on cardiovascular health (which is named the hybrid program hereafter) in adult patients (18 years or older) with atherosclerotic cardiovascular disease. Furthermore, we seek to answer how much patients adhere to and are satisfied with implementing the hybrid program, and what problems executing this program will bring for patients. conditions: Atherosclerosis conditions: Coronary Artery Disease conditions: Peripheral Arterial Disease conditions: Ischemic Stroke conditions: Carotid Artery Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants undergo permuted block randomization with block sizes of four via a web-based system will be used for the study, in a 1:1 ratio between the hybrid strategy or control arms. primaryPurpose: OTHER masking: NONE count: 50 type: ESTIMATED name: Hybrid strategy measure: Feasibility of conducting the trial measure: Adherence to the individual components of the hybrid strategy measure: Patient satisfaction with the hybrid strategy measure: Any potential adverse events in intervention and control groups during the 30-day follow-up measure: Change in the health-related quality of life measure: Change in the level of anxiety sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rajaie Cardiovascular Medical and Research Center status: RECRUITING city: Tehran zip: 1995614331 country: Iran, Islamic Republic of name: Parham Sadeghipour, MD role: CONTACT phone: +98 21 2392 2092 email: psadeghipour@rhc.ac.ir lat: 35.69439 lon: 51.42151 hasResults: False
nctId: NCT06261593 id: Ankle-Blood briefTitle: Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Ankle Arthropathy overallStatus: RECRUITING date: 2024-04-06 date: 2024-07-03 date: 2024-09-20 date: 2024-02-15 date: 2024-02-20 name: Investigación en Hemofilia y Fisioterapia class: NETWORK briefSummary: Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy.
Study design. Randomized, multicenter, single-blind clinical study. Method. 32 patients with hemophilia A and B will be recruited in this study. Patients will be recruited in 4 regions of Spain. The dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (SF-36 scale), joint status (Hemophilia Joint Health Score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and stability (The Single Leg Stance Test). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks.
Expected results. Observe the safety of blood flow restriction in hemophilia patients. To analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, stabilit, and the perception of quality of life in patients with hemophilic ankle arthropathy. conditions: Hemophilia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Blood flow restriction measure: Change from baseline hemarthrosis after treatment and at 4 weeks measure: Change from baseline pressure pain threshold after treatment and at 4 weeks measure: Change from baseline muscle strength after treatment and at 4 weeks measure: Change from baseline electrical activity of the muscles after treatment and at 4 weeks measure: Change from baseline joint status after treatment and at 4 weeks measure: Change from baseline range of motion after treatment and at four weeks measure: Change from baseline balance after treatment and at four weeks sex: MALE minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: University of Oviedo status: RECRUITING city: Oviedo state: Asturias zip: 33006 country: Spain name: Rubén Cuesta-Barriuso, PhD role: CONTACT lat: 43.36029 lon: -5.84476 hasResults: False
nctId: NCT06261580 id: TP-CLN-100502 briefTitle: Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers overallStatus: COMPLETED date: 2021-07-28 date: 2021-10-25 date: 2021-10-25 date: 2024-02-15 date: 2024-02-15 name: Haemonetics Corporation class: INDUSTRY name: Machaon Diagnostics name: ClinStatDevice briefSummary: This trial holds minimal risk to the trial volunteers and consists of obtaining whole blood via venipuncture to perform coagulation parameter measurements to define a Normal Reference Range.
Written consent to participate in the study will be obtained prior to volunteer screening per site procedures. conditions: Healthy studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 181 type: ACTUAL name: TEG 6s Citrated K, KH, RTH, and FFH Cartridge name: Clauss Fibrinogen measure: CK-MA TEG Parameter measure: CK-R TEG Parameter measure: CKH-MA TEG Parameter measure: CKH-R TEG Parameter measure: CKH-LY30 TEG Parameter measure: CRTH-MA TEG Parameter measure: CFFH-MA TEG Parameter sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Machaon Diagnostics city: Oakland state: California zip: 94609 country: United States lat: 37.80437 lon: -122.2708 facility: Cardiovascular Research Institute - Loyola University Chicago Health Sciences city: Maywood state: Illinois zip: 60153 country: United States lat: 41.8792 lon: -87.84312 facility: Louisiana Coagulation / Machaon Division city: New Orleans state: Louisiana zip: 70118 country: United States lat: 29.95465 lon: -90.07507 hasResults: False
nctId: NCT06261567 id: D2287R00189 briefTitle: A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service acronym: REMISSION UK overallStatus: RECRUITING date: 2024-02-27 date: 2024-09-27 date: 2024-09-27 date: 2024-02-15 date: 2024-04-23 name: AstraZeneca class: INDUSTRY briefSummary: Asthma is a common lung condition that causes occasional breathing difficulties and affects around 5.4 million people in the UK of all ages. Common symptoms can include wheezing when breathing, breathlessness, a tight chest and coughing. However, these symptoms can get worse and lead to an asthma attack which can be fatal.
There is currently no cure for asthma but there are treatments that can help keep the symptoms under control. The main types of treatment include reliever inhalers used when needed quickly to reverse asthma symptoms for a short time, and preventer inhalers that are used everyday to prevent symptoms for starting. Unfortunately, not all patients are able to control their asthma on these treatments alone. Biologic treatments, also known as monoclonal antibodies, have been introduced to treat certain types of severe asthma over recent years. These specialist treatments use antibodies produced from cells in a laboratory to help reduce inflammation and might offer the possibility of higher levels of disease control including the reduction or absence of symptoms and normal lung function. This higher level of disease control is called remission.
This study aims to understand whether or not remission is possible in patients with severe asthmas treated with biologics in the NHS. This study will take place a 4 specialist asthma centres in the UK and seeks to include retrospective data from approximately 450 adult patients that were treated with biologics as part of routine care between 01 October 2021 and 30 September 2022. Data will be collected directly from medical records and entered into the study database in a pseudonymised format by members of the direct care team ready for analysis. conditions: Asthma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 425 type: ESTIMATED name: Biologic treatment measure: Proportion of patients in clinical remission measure: Number and proportion achieving specific criteria for clinical remission measure: Number and proportion of super-responders measure: Number and proportion of responders measure: Number and proportion of non-responders measure: Age at index measure: Sex measure: Ethnicity measure: Smoking status measure: BMI measure: IMD quintile measure: Comorbidities measure: COVID-19 vaccination status measure: Fractional Exhaled Nitric Oxide (FeNO) measure: Blood eosinophil count (EOS) measure: IgE measure: ACQ-6 measure: AQLQ measure: lung function (FEV1) measure: Rate of exacerbation in prior 12 months measure: Asthma treatments at 6 months measure: Asthma treatments at 12 months measure: Annualised exacerbation rate (AER) measure: mOCS use (proportion with 0 mg/day) measure: ACQ-6 score measure: AQLQ score measure: Lung function (FEV-1) measure: Respiratory infections measure: Annualised exacerbation rate (AER) measure: mOCS use (proportion with 0 mg/day) measure: ACQ-6 score measure: AQLQ score measure: Lung function (FEV-1) measure: Respiratory infections sex: ALL minimumAge: 18 Years maximumAge: 130 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site status: NOT_YET_RECRUITING city: Birmingham country: United Kingdom lat: 52.48142 lon: -1.89983 facility: Research Site status: RECRUITING city: London country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Research Site status: NOT_YET_RECRUITING city: Manchester country: United Kingdom lat: 53.48095 lon: -2.23743 facility: Research Site status: RECRUITING city: Southampton country: United Kingdom lat: 50.90395 lon: -1.40428 hasResults: False
nctId: NCT06261554 id: Low-dose sesame OIT briefTitle: Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients overallStatus: RECRUITING date: 2024-03 date: 2026-03-01 date: 2027-03-01 date: 2024-02-15 date: 2024-03-05 name: Medical University of Warsaw class: OTHER briefSummary: It is a randomized, single-center, controlled trial to evaluate the effectiveness of oral immunotherapy with low-dose sesame protein compared with standard treatment (elimination diet) in patients with sesame allergy. conditions: Food Allergy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 39 type: ESTIMATED name: Dietary Supplement: Low dose OIT measure: Tolerance of sesame measure: Adverse event measure: Laboratory data measure: Basophil activation test measure: Skin prick test (SPT) measure: Desensitization dose sex: ALL minimumAge: 3 Years maximumAge: 17 Years stdAges: CHILD facility: Medical University of Warsaw status: RECRUITING city: Warsaw state: Mazowieckie zip: 02-091 country: Poland name: Katarzyna Grzela, PhD, MD role: CONTACT phone: +48 22 3179431 email: katarzyna.grzela@wum.edu.pl lat: 52.22977 lon: 21.01178 hasResults: False
nctId: NCT06261541 id: ABLEexoMS briefTitle: Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting overallStatus: RECRUITING date: 2024-04-08 date: 2024-08-01 date: 2024-08-01 date: 2024-02-15 date: 2024-04-22 name: ABLE Human Motion S.L. class: INDUSTRY name: Fundación Esclerosis Múltiple Madrid (FEMM) briefSummary: The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting. Furthermore, the potential effects of the training on walking, and balance function, general health status, user satisfaction, and quality of life will be assessed. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: ABLE Exoskeleton measure: Number and type of device-related Adverse Events measure: Level of Assistance (LoA) to don/doff the device measure: Time taken to don/doff the device measure: Level of Assistance (LoA) to complete therapy activity tasks measure: Time spent upright and time spent walking measure: Number of steps walked measure: Distance walked measure: Timed 25-Feet Walk test (T25FW) measure: Ambulation Index (AI) measure: 6-Minute Walk Test (6MWT) measure: Timed Up-and-Go test (TUG) measure: Trunk Impairment Scale (TIS) measure: Lower extremity muscle strenght measure: Modified Ashworth Scale (MAS) measure: Borg Rating of Perceived Exertion measure: Barthel Index (BI) score measure: Modified Fatigue Impact Scale (MFIS) score measure: Multiple Sclerosis Quality of Life-54 (MSQoL-54) measure: Psychosocial Impact of Assistive Devices Scale (PIADS) score measure: Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) score sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fundación Esclerosis Múltiple Madrid (FEMM) status: RECRUITING city: Madrid country: Spain name: Almudena Chao role: CONTACT phone: 913993245 email: achao@femmadrid.org name: Kenneth Malpartida role: CONTACT email: kmalpartida@femmadrid.org lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06261528 id: STU-2023-1289 briefTitle: Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis acronym: NO-FATIGUE overallStatus: RECRUITING date: 2024-04-18 date: 2025-05-01 date: 2025-12-01 date: 2024-02-15 date: 2024-04-22 name: University of Texas Southwestern Medical Center class: OTHER name: National Multiple Sclerosis Society name: International Progressive Multiple Sclerosis Alliance briefSummary: The study is being done to determine if treatment with a novel form of light therapy is tolerated in patients with progressive multiple sclerosis. The goal of this trial to establish the safety profile of this light therapy while generating data on its impact on fatigue, as well as its mechanism of action. Fatigue is often a complex symptom in multiple sclerosis, without any FDA-approved direct therapy. Fatigue is traditionally treated with symptom management through a multidisciplinary team. conditions: Progressive Multiple Sclerosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This will be an open label, single arm, single center phase 1 research study designed to generate safety data, biomarker data, and preliminary efficacy data to reduce fatigue in patients with progressive MS, to include PPMS and SPMS primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Light therapy measure: Treatment Emergent Adverse Events (TEAEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UT Southwestern Medical Center status: RECRUITING city: Dallas state: Texas zip: 75247 country: United States name: Ana Raicu role: CONTACT phone: 214-645-0292 email: ana.raicu@utsouthwestern.edu name: Ana Raicu role: CONTACT phone: 214-645-0292 name: Peter Sguigna, MD role: PRINCIPAL_INVESTIGATOR name: Benjamin Greenberg, MD role: SUB_INVESTIGATOR lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06261515 id: Perio-gut PRIN briefTitle: Multi-omics Analysis of Oral-gut Microbial Profiles overallStatus: NOT_YET_RECRUITING date: 2024-02-15 date: 2026-01-15 date: 2026-02-15 date: 2024-02-15 date: 2024-02-15 name: University of Turin, Italy class: OTHER briefSummary: Periodontitis is a chronic inflammatory disease of the tooth supporting structures induced by a dysbiosis in the oral and subgingival microenvironment of susceptible patients. The long-term swallowing of high doses of periodontal pathogenic microorganisms could induce a dysbiosis of the intestinal microbiota, favouring the establishment of an 'inflamed' microbiome in terms of composition and/or function. The present project is aimed at a better understanding of the etiopathogenetic correlation between periodontitis and intestinal dysbiosis, and aims to explore the hypothesis that periodontal treatment may influence the multi-omics profile on the oral-gut-systemic axis. 70 patients affected by stage III-IV periodontitis will be recruited, and treated by means of full-mouth scaling and root planing. Salivary, subgingival plaque, plasma and stool samples, together with a complete periodontal charting and a food diary will be collected and compared at baseline and after treatment. Age, gender and BMI-matched healthy individuals will be recruited as controls. conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: Active periodontal treatment measure: Changes in gut microbial profile measured in stool samples measure: Changes in oral microbial profile measured in saliva samples measure: Changes in oral microbial profile measured in subgingival plaque samples measure: Changes in oral-gut metabolome measured in stool samples measure: Changes in oral-gut miRNAome measured in stool samples measure: Metabolic plasma changes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06261489 id: REB23-1128 briefTitle: Cannabis (THC vs. CBD) in Multiple Sclerosis overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-09 date: 2025-12 date: 2024-02-15 date: 2024-02-15 name: University of Calgary class: OTHER name: Multiple Sclerosis Society of Canada briefSummary: The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS).
Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks. conditions: Multiple Sclerosis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: THC name: CBD measure: Cognitive outcome: The Differential Effect, if any, of THC and CBD in MS Cognition will be measured by Symbol Digit Modality Test (SDMT). measure: NLUTD outcome: The Differential Effect, if any, of THC and CBD on Neurogenic lower urinary tract dysfunction (NLUTD) symptoms will be measured by Neurogenic Bladder Symptom Score (NBSS). measure: Blinding feasibility: The ability to blind the administration of THC vs CBD in PwMS will be evaluated based on participants and investigators report. sex: ALL minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT hasResults: False
nctId: NCT06261476 id: DYP-Pharm-RP-23 briefTitle: Safety of Ashwagandha (Withania Somnifera) Root Extract overallStatus: RECRUITING date: 2024-02 date: 2024-05 date: 2024-05 date: 2024-02-15 date: 2024-02-15 name: SF Research Institute, Inc. class: NETWORK briefSummary: The primary objective is to evaluate the laboratory safety of Ashwagandha standardized root extract 500 mg capsules in healthy adults over 12-week therapy based on Complete Blood Count, Renal Function Test, Liver Function Test, Lipid Profile and Thyroid Function Test, Fasting blood sugar and HbA1c Test. The secondary objectives are to evaluate the clinical safety of Ashwagandha standardized root extract 500 mg capsules in healthy adults over 12-week therapy and to evaluate the effect of the Ashwagandha standardized root extract 500 mg on Quality of Life (QoL) using the SF-36 tool. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Ashwagandha (Withnia somnifera) measure: Hemoglobin Test measure: Total Erythrocyte Count measure: Total Leukocyte Count measure: Platelet Count measure: Hematocrit Test measure: Total Cholesterol Test measure: LDL Test measure: HDL Test measure: Triglycerides Test measure: Serum Alkaline Transaminase Test measure: Aspartate Transaminase Test measure: Alkaline Phosphatase Test measure: Bilirubin Test measure: Serum Creatinine Test measure: Blood Urea Nitrogen Test measure: T4 measure: T3 measure: Serum TSH measure: Fasting Blood Sugar measure: HbA1c measure: Adverse Events measure: Quality of Life (SF-36 QoL) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SF Research Institute status: RECRUITING city: San Francisco state: California zip: 94127 country: United States name: John Ademola, PhD role: CONTACT phone: 415-549-9362 email: studyrecruitment@sfinstitute.com lat: 37.77493 lon: -122.41942 hasResults: False
nctId: NCT06261450 id: 2020-3424 id: 236114 type: OTHER domain: Health Canada id: 202010PJT-451514 type: OTHER_GRANT domain: Canadian Institutes of Health Research briefTitle: Effect of CBD on the Brain overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-08-15 date: 2027-08-15 date: 2024-02-15 date: 2024-02-15 name: Université de Sherbrooke class: OTHER name: Canadian Institutes of Health Research (CIHR) name: Jazz Pharmaceuticals name: Centre de recherche du Centre hospitalier universitaire de Sherbrooke briefSummary: This proposal focuses on the therapeutic relevance of the endocannabinoid (eCB) system for the treatment of Fragile-X syndrome (FXS), the primary hereditary cause of autism spectrum disorder (ASD). Although most individuals with FXS have moderate to severe intellectual disability (ID), caregivers are mainly concerned about aggressive behavior and anxiety problems, hallmark features of the condition. Concurrent lines of evidence suggest that targeting the endocannabinoid (eCB) system by administration of cannabidiol (CBD) could upregulate GABAergic functions and correct inhibitory deficits presumed responsible for the neuropsychiatric phenotype of FXS. However, the eCB system and its effect on the brain remains unexplored in FXS patients. This clinical trial aims to define the therapeutic relevance of the eCB system for FXS using a multimodal neuroimaging approach to finely characterize the acute effects of oral CBD on the principal inhibitory neurotransmitter system (GABA) in a large cohort of FXS patients. conditions: Fragile X Syndrome studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This study is a double-blind-crossover placebo control comparing the acute effect of oral CBD in patients with FXS to controls. primaryPurpose: BASIC_SCIENCE masking: TRIPLE maskingDescription: Randomization and dispensing of active and control will be conducted by the research center pharmacy. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: CBD Oral Solution (eCBD system Target) name: Placebo measure: Short Intracortical Inhibition measure: Intracortical Facilitation measure: Gaba concentration levels sex: ALL minimumAge: 7 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT hasResults: False